Feasibility, Acceptability and Costs of a Multiple First-lines Artemisinin-based Combination Therapies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

150000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-10

Study Completion Date

2021-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A simultaneous deployment of multiple first line therapies (MFT) for uncomplicated malaria using artemisisin based combination therapies as showed by theoretical models, may extend the useful therapeutic life of the current Artemisinin-based combination thérapies (ACTs) by reducing drug pressure and slowing the spread of resistance without putting life at risk. We therefore hypothesized that a simultaneous deployment of three ACTs targeting three segments of the population is feasible, acceptable and can achieve high coverage rate if potential barriers are well identified, well addressed and the key implementers are well-trained and adequately supported. To test this hypothesis, a quasi-experimental study will be conducted.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children

NCT00406146

Uncomplicated Malaria

UNKNOWN PHASE3

Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2)

NCT04778813

Malaria Burkina Faso

UNKNOWN PHASE4

Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso

NCT01017770

Uncomplicated P. Falciparum Malaria in Children

COMPLETED PHASE4

In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso

NCT00808951

Malaria

COMPLETED PHASE4

Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso

NCT04695197

Covid-19 Malaria

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be conducted through four overlapping phases: formative research phase, the MFTs deployment phase, the evaluation phase and the post-evaluation phase.

1. Formative research phase

1.1 Objective

Generate baseline information and to develop intervention tools for the pilot implementation of MFTs for uncomplicated malaria in the study area.

1.2 Design

Cross-sectional surveys using desk reviews, qualitative and quantitative research methods:
* Individual in-depth Interviews
* Focus group discussions
* Household surveys for the assessment of malaria-related morbidity and mortality at community level as well as the healthcare system utilisation
* Health facility-based surveys for malaria morbidity and mortality, antimalarial drugs and malaria rapid diagnostic tests availability.

1.3 Duration

Six months from obtaining the approval of the ethics committee for health research.
2. MFTs deployment phase

2.1 Objective

Implement the MFTs for uncomplicated malaria in the health district of Kaya that is feasible, acceptable and achieve high coverage rate.

2.2 Drugs deployment

Study ACTs and respective target populations:
* Artesunate-Pyronaridine for children less than five years of age
* Artemether-Lumefantrine for pregnant women
* Dihydroartemisinin-Piperaquine for individuals five years of age and above

NB: Community case management of malaria using Artemether-Lumefantrine as per National Malaria Control Program recommendation.

2.3 Duration

Twelve months including low and high malaria transmission seasons in the study area.
3. Monitoring and evaluation phase

3.1 Objectives

Assess the feasibility, the acceptability, the cost and the effects of the pilot MFTs pilot programme for uncomplicated malaria in the health district of Kaya.

3.2 Design

Cross-sectional surveys using desk review, qualitative and quantitative research methods:
* Individual in-depth Interviews
* Focus group discussions
* Household surveys for the assessment of malaria-related morbidity and mortality at community level as well as the healthcare system utilisation
* Health facility-based surveys for malaria-related morbidity and mortality, the availability and use of antimalarial drugs and malaria rapid diagnostic tests.
* Costs assessments.

3.3 Duration

Four months.
4. Post-evaluation phase

4.1 Objectives

Communicating and disseminating the findings of the pilot implementation of multiple first-lines artemisinin-based combination therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso;

4.2 Methodology

* Feedback meetings for reporting to local communities
* National workshop aiming at reporting the programme findings
* Final report to be submitted to the donor
* Oral presentations of findings at congresses, conferences, seminars and publication of findings in peer-reviewed scientific journals

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malaria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children under-five

Uncomplicated malaria case in this group will be managed using Pyronaridine-Artesunate at health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.

No interventions assigned to this group

Individuals five years of age and above

Uncomplicated malaria case in this group will be managed using Dihydoartemisinin-Piperaquine health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.

No interventions assigned to this group

Pregnant women

Uncomplicated malaria case in this group will be managed using Artemether-Lumefantrin health facility level. This drug is registered in Burkina Faso for routine medical care for uncomplicated malaria case.

No interventions assigned to this group